抗原负载DC―CIK联合化疗治疗晚期恶性黑色素瘤临床研究.docVIP

抗原负载DC―CIK联合化疗治疗晚期恶性黑色素瘤临床研究 　　[摘要]目的：研究抗原负载的DC-CIK过继免疫疗法联合化疗对晚期恶性黑色素瘤的临床疗效。方法：选取郑州大学第一附属医院收治的60例晚期恶性黑色素瘤患者，28例行抗原负载的DC-CIK联合化疗（A组），32例行单纯化疗（B组），对两组患者治疗后免疫功能、生活质量、中位生存期及无进展生存期进行比较。结果：A组治疗后外周血中CD3+， CD3+/CD4+， CD3+/CD8+， CD4+/CD8+和CD16+/CD56+细胞比值无明显变化，（P0.05）；B组治疗后外周血中T细胞亚群比例较之前显著下降，（P0.05）。结论：抗原负载的DC-CIK细胞联合化疗治疗晚期恶性黑色素瘤安全有效，在提高患者免疫功能、减轻化疗不良反应、延长无进展生存期和改善患者生活质量方面具有重要作用。 　　[关键词]树突状细胞；细胞因子诱导的杀伤细胞；恶性黑色素瘤；化疗 　　[中图分类号]R739.5 [文献标志码]A [文章编号]1008-6455（2015）02-0025-06 　　Clinical study on DC-CIK loaded with antigen combined with chemotherapy in the treatment of end-stage malignant melanoma 　　LIU Yang， LIU Lin-bo 　　（Department of Plastic Surgery，The First Affiliated Hospital of Zhengzhou University， Zhengzhou 450052，Hennan，China） 　　Abstract： Objective To evaluate the therapeutic effect of dendritic cells-cytokine icduced killers cells（DC-CIK） loaded with antigen chemotherapy in the treatment of end-stage malignant melanoma （MM）. Methods 60 MM patients were selected from the First Affiliated Hospital of Zhengzhou University. 28 of them were treated by DC-CIK loaded with antigen with chemotherapy（A group）， and another 32 were treated by chemotherapy only （B group）. The immune function， quality of life （QOL）， the median progression-free survival （mPFS） and overall survival（OS） of the patients were compared between the two groups after the treatment. Results There was no obvious change of the ratio of CD3+， CD3+/CD4+， CD3+/CD8+， CD4+/CD8+ and CD16+/CD56+ in the peripheral blood of group A（P0.05）， while T cell subsets decreased significantly after the treatment of group B， and obviously lower than that of group A（P0.05）. Conclusions Treatment with DC-CIK adoptive immunotherapy combined with chemotherapy can improve effectively the immune function and reduced the side effects of chemotherapy， prolong the PFS， and improve QOL of end-stage MM patients. 　　Key words：dendritic cells（DC）； cytokine induced killer cells（CIK）； malignant melanoma； chemotherapy 　　黑色素瘤是一种临床上发病率增长最快的恶性